<html>
<head>
<META http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>NCT00120900 on 2005_12_08: ClinicalTrials.gov Archive</title>
<link rel="stylesheet" href="/archive/history.css">
<link rel="stylesheet" href="/archive/received.css">
</head>
<body class="received">
<div class="navTop"><table class="navTopTriptych"><tr><td class="navTopTriptychL"><img src="/archive/ctgov_logo_ttl.gif" alt="ClinicalTrials.gov" width="360" height="47" /></td><td class="navTopTriptychC" style="background-image: url(/archive/ctgov_logo_ttm.gif)" /><td class="navTopTriptychR"><img src="/archive/ctgov_logo_ttr.gif" alt="Linking patients to medical research" width="314" height="47" /></td></tr></table></div>
<div id="navLinks" class="navLinks"><a href="/archive/NCT00120900">&#8592; History of this study</a><a href="http://clinicaltrials.gov/show/NCT00120900">&#8593; Current version of this study</a></div><h1>View of NCT00120900 on
  2005_12_08</h1>
<table class="info">
<tr>
<th nowrap>ClinicalTrials Identifier:</th><td>NCT00120900</td>
</tr>
<tr>
<th>Updated:</th><td>2005_12_08</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Descriptive Information</h2>
</th>
</tr>
<tr>
<th>Brief title</th><td>
<p>Osteoarthritis Of The Knee</p>
</td>
</tr>
<tr>
<th>Official title</th><td>
<p>A Phase III, 12-Week, Multicentre, Double-Blind, Double-Dummy, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381 1mg, 5mg, 10mg, 25mg and 50mg Administered Orally Once Daily, in Adults With Osteoarthritis of the Knee (CXA30007).</p>
</td>
</tr>
<tr>
<th>Brief summary</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>The purpose of this study is to evaluate the effectiveness of GW406381 (a COX-2 inhibitor) in treating the signs and symptoms of osteoarthritis of the knee.</p>
</td>
</tr>
<tr>
<th>Detailed description</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p></p>
</td>
</tr>
<tr>
<th>Phase</th><td>Phase 3</td>
</tr>
<tr>
<th>Study type</th><td>Interventional</td>
</tr>
<tr>
<th>Study design</th><td>Treatment</td>
</tr>
<tr>
<th>Study design</th><td>Randomized</td>
</tr>
<tr>
<th>Study design</th><td>Double Blind</td>
</tr>
<tr>
<th>Study design</th><td>Placebo Control</td>
</tr>
<tr>
<th>Study design</th><td>Parallel Assignment</td>
</tr>
<tr>
<th>Study design</th><td>Safety/Efficacy Study</td>
</tr>
<tr>
<th>Primary outcome</th><td>Measure: 
         Change in OA symptoms at week 12 as measured by scores on subject-completed questionnaires on pain, daily activities and global assessment
      </td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: 
         Change in OA symptoms as measured by subject and physician-completed questionnaires at each scheduled visit.  Percentage of responders, subjects discontinuing due to lack of efficacy, use of rescue medication and health-related quality of life.
      </td>
</tr>
<tr>
<th>Condition</th><td>
         Osteoarthritis of the Knee
      </td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: GW406381</div>
</td>
</tr>
<tr>
<th>Reference</th><td>
<div>Citation: </div>
<div>MEDLINE: </div>
</td>
</tr>
<tr>
<th>URL</th><td>http://</td>
</tr>
<tr>
<th>See also</th><td>
<p></p>
</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Recruitment Information</h2>
</th>
</tr>
<tr>
<th>Status</th><td>
            Recruiting
         </td>
</tr>
<tr>
<th>Start date</th><td>
         2005-05
      </td>
</tr>
<tr>
<th>Criteria</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>Inclusion criteria:<br>
<br> &nbsp;- Subjects have a primary diagnosis of osteoarthritis of the knee with symptom duration of at least 3 months.<br>
<br> &nbsp;- Use pain medication, such as a COX-2 inhibitor or NSAID (non-steroidal anti-inflammatory drug) at least 5 days per week.<br>
<br>Exclusion criteria:<br>
<br> &nbsp;- History of hypersensitivity or intolerance to pain medications.<br>
<br> &nbsp;- History of gastroduodenal perforations and/or obstructions.<br>
<br> &nbsp;- History of upper GI (gastrointestinal) ulceration within the previous 6 months.<br>
<br> &nbsp;- History of upper or lower GI bleeding within the previous year.<br>
<br> &nbsp;- History of inflammatory bowel disease.<br>
<br> &nbsp;- Currently take sucralfate or misoprostol.<br>
<br> &nbsp;- Currently taking aspirin daily for the heart.<br>
<br> &nbsp;- Other restrictions around the use medications apply and would need to be discussed.<br>
<br> &nbsp;- History of coronary artery disease, (angina, MI) or surgery.<br>
<br> &nbsp;- History of congestive heart failure or renal artery stenosis.<br>
<br> &nbsp;- History of stroke or transient ischemic attack.<br>
<br> &nbsp;- History of uncontrolled hypertension.</p>
</td>
</tr>
<tr>
<th>Gender</th><td>
            Both
         </td>
</tr>
<tr>
<th>Minimum age</th><td>40 Years</td>
</tr>
<tr>
<th>Maximum age</th><td>N/A</td>
</tr>
<tr>
<th>Healthy volunteers</th><td>No</td>
</tr>
<tr>
<th>Expected enrollment</th><td>1113</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Administrative Data</h2>
</th>
</tr>
<tr>
<th>Organization name</th><td>GlaxoSmithKline</td>
</tr>
<tr>
<th>Organization study ID</th><td>CXA30007</td>
</tr>
<tr>
<th>Sponsor</th><td>
               GlaxoSmithKline
            </td>
</tr>
<tr>
<th>Collaborator</th><td>
               
            </td>
</tr>
<tr>
<th>Health Authority</th><td>
               United States: Food and Drug Administration
         </td>
</tr>
</table><div class="navBottom"><div class="navBottomLine" style="background-image: url(/archive/ctgov_logo_ttm.gif)">&#160;</div><div class="navBottomLinks">&#160;</div></div></body>
</html>
